Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.

McEwan P, Bøg M, Faurby M, Foos V, Lingvay I, Lübker C, Miller R, Toliver JC, Yeates F, Lincoff AM

Journal of medical economics12 Feb 2025Cited by 14 (Europe PMC)

PMID39882599DOI10.1080/13696998.2025.2459529PepBankPUB-39882599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01Computer modelIn silicoEfficacy outcome
In a model of adults with overweight or obesity and cardiovascular disease, semaglutide 2.4 mg avoided 2,791 non-fatal myocardial infarctions per 100,000 subjects.
In plain wordsIn a computer model, semaglutide 2.4 mg avoided heart attacks in a simulated group with obesity and heart disease, compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseNon-fatal myocardial infarctions avoided (modelled)
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Non-fatal MI avoided
2791 per 100,000 subjects
lifetime
Source sentences
Summary
Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259901
02Computer modelIn silicoEfficacy outcome
In a model of adults with overweight or obesity and cardiovascular disease, semaglutide 2.4 mg avoided 3,000 coronary revascularizations per 100,000 subjects.
In plain wordsIn a computer model, semaglutide 2.4 mg avoided heart procedures in a simulated group with obesity and heart disease, compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseCoronary revascularizations avoided (modelled)
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Coronary revascularizations avoided
3000 per 100,000 subjects
lifetime
Source sentences
Summary
Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259902
03Computer modelIn silicoEfficacy outcome
In a model of adults with overweight or obesity and cardiovascular disease, semaglutide 2.4 mg avoided 487 non-fatal strokes per 100,000 subjects.
In plain wordsIn a computer model, semaglutide 2.4 mg avoided strokes in a simulated group with obesity and heart disease, compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseNon-fatal strokes avoided (modelled)
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Non-fatal strokes avoided
487 per 100,000 subjects
lifetime
Source sentences
Summary
Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259903
04Computer modelIn silicoEfficacy outcome
In a model of adults with overweight or obesity and cardiovascular disease, semaglutide 2.4 mg avoided 115 cardiovascular deaths per 100,000 subjects.
In plain wordsIn a computer model, semaglutide 2.4 mg avoided heart-related deaths in a simulated group with obesity and heart disease, compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular deaths avoided (modelled)
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
CV deaths avoided
115 per 100,000 subjects
lifetime
Source sentences
Summary
Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259904
05Computer modelIn silicoOther
In the model, average lifetime treatment costs with semaglutide 2.4 mg were $47,353 per subject.
In plain wordsIn the model, semaglutide 2.4 mg treatment cost about $47,353 per person over a lifetime.
Peptide
Semaglutide
Outcome
Not applicableAverage lifetime treatment cost per subject
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Lifetime treatment cost
47,353 USD
per subject
Source sentences
Summary
Average per-subject lifetime treatment costs were $47,353
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259905
06Computer modelIn silicoOther
In the model, avoided type 2 diabetes saved $14,431 per subject.
In plain wordsIn the model, preventing type 2 diabetes with semaglutide saved about $14,431 per person.
Peptide
Semaglutide
Outcome
Not applicableSavings from avoided type 2 diabetes
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Savings from avoided T2D
14,431 USD
per subject
Source sentences
Summary
savings arose from avoided T2D ($14,431)
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259906
07Computer modelIn silicoOther
In the model, avoided chronic kidney disease saved $2,074 per subject.
In plain wordsIn the model, preventing kidney disease with semaglutide saved about $2,074 per person.
Peptide
Semaglutide
Outcome
Not applicableSavings from avoided chronic kidney disease
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Savings from avoided CKD
2074 USD
per subject
Source sentences
Summary
CKD ($2,074)
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259907
08Computer modelIn silicoOther
In the model, avoided cardiovascular events saved $1,512 per subject.
In plain wordsIn the model, preventing heart events with semaglutide saved about $1,512 per person.
Peptide
Semaglutide
Outcome
Not applicableSavings from avoided cardiovascular events
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Savings from avoided CV events
1512 USD
per subject
Source sentences
Summary
CV events ($1,512)
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259908
09Computer modelIn silicoOther
In the model, semaglutide 2.4 mg was associated with increased lifetime costs of $29,767.
In plain wordsIn the model, semaglutide 2.4 mg raised lifetime costs by about $29,767 per person.
Peptide
Semaglutide
Outcome
IncreaseIncremental lifetime costs
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
Incremental lifetime cost
29,767 USD
per subject
Source sentences
Summary
Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767)
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259909
10Computer modelIn silicoOther
In the model, semaglutide 2.4 mg gave 0.218 additional QALYs.
In plain wordsIn the model, semaglutide 2.4 mg added about 0.218 years of good-quality life per person.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life years gained
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
QALYs gained
0.218 QALY
per subject
Source sentences
Summary
additional QALYs gained (0.218)
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259910
11Computer modelIn silicoOther
In the model, the incremental cost-effectiveness ratio of semaglutide 2.4 mg was $136,271 per QALY at list price.
In plain wordsIn the model, semaglutide 2.4 mg cost about $136,271 for each year of good-quality life gained at list price.
Peptide
Semaglutide
Outcome
Not applicableIncremental cost-effectiveness ratio at list price
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
ICER
136,271 USD/QALY
list price
Source sentences
Summary
an incremental cost-effectiveness ratio of $136,271/QALY at list price
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259911
12Computer modelIn silicoOther
In a model scenario with an estimated 48% rebate, the incremental cost-effectiveness ratio was $32,219 per QALY.
In plain wordsIn a model scenario with a 48% rebate, semaglutide 2.4 mg cost about $32,219 for each year of good-quality life gained.
Peptide
Semaglutide
Outcome
Not applicableIncremental cost-effectiveness ratio with 48% rebate
Study
n = 100,000
Markov-state cost-effectiveness model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
2.4 mg · 2.79 yearsAs given in this study.
Measurements
ICER
32,219 USD/QALY
48% rebate scenario
Source sentences
Summary
a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed.
Summary · context
A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment.
Report a problemFND-3988259912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Novo Nordisk A/Sn = 17,60424 Oct 2018 to 29 Jun 2023

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 30 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.